The first patient in The Netherlands has been treated with an innovative implant designed to address chronic migraine, marking a significant milestone in ongoing clinical research, say scientists.
The procedure was conducted at Erasmus MC in Rotterdam as part of a trial investigating a promising new therapy, and which is also being conducted in Australia and Belgium.
Developed by pioneering Dutch company Salvia BioElectronics, it involves implanting two ultra-thin devices beneath the skin – one near the forehead and the other near the back of the head. These emit gentle electrical pulses aimed at nerves involved in migraine attacks.
A wearable external device allows patients to activate the therapy with the push of a button, potentially reducing the frequency and intensity of migraine episodes.
The technology, known as neuromodulation, has been successfully used for decades to treat other neurological disorders, including Parkinson’s disease and epilepsy, and has shown positive results in treating cluster headaches.
“Our nervous system uses electrical signals to control how our body moves, feels, and functions,” Professor Dr Frank Huygen, Chair of Anaesthesiology at Erasmus MC who performed the first implantation, told NL Times. “In migraines, these signals can become imbalanced. Neuromodulation can help correct this disruption and restore balance.”
Salvia BioElectronics has been developing the migraine therapy since 2017. While pilot studies have yielded promising results, further research is needed to confirm its long-term effectiveness and safety.
The RECLAIM study includes participants from Erasmus MC and St Antonius Ziekenhuis in Utrecht/Nieuwegein.
Dr Harold Nijhuis, anaesthesiologist and pain specialist at St Antonius Ziekenhuis, emphasised the potential of neuromodulation for patients who don’t find relief from conventional medications.
“Neuromodulation could provide a breakthrough. Early pilot study results have been promising, and we are excited to contribute to the RECLAIM study, which could offer a treatment option that significantly improves patients’ quality of life.”
See more from MedicalBrief archives:
Significant improvements with surgical treatment for migraine
Mobile app helps predict migraine triggers – US study
Migraines a significant risk factor for dementia